Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

▤ Summary

Immutep will present positive interim Phase I data for IMP761 at EULAR 2026. The study met its primary endpoint and showed favorable safety, tolerability, and statistically significant pharmacodynamic activity in healthy volunteers. The results support further clinical evaluation of IMP761 in autoimmune diseases, including a planned Phase II setting. Immutep says the data also strengthens the case for potential strategic collaboration around the program.

▦ Linked Companies